Skip to main content
VTVT
NASDAQ Life Sciences

vTv Therapeutics Stockholders Express Significant Dissent on Director Elections and Executive Pay

Analysis by Wiseek AI
Sentiment info
Negative
Importance info
8
Price
$36.27
Mkt Cap
$142.864M
52W Low
$14
52W High
$44
52W Position info
159% above low
Off High info
18% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

VTVT has more than doubled off its 52-week low of $14.

Summary

vTv Therapeutics' annual meeting showed significant shareholder dissent, with high 'withheld' votes for several directors and very low support for executive compensation, signaling governance concerns.


Key Events · Corporate Governance and Compliance · VTVT

  • Significant Director Dissent

    Five out of seven director nominees (Srinivas Akkaraju, Raymond Cheong, Anne Phillips, Paul Sekhri, and Daniel K. Spiegelman) received more 'withheld' votes than 'for' votes, indicating substantial shareholder dissatisfaction despite their election.

  • Executive Compensation Rejected

    The non-binding advisory vote on executive compensation received very low support, with only 25.8% of votes cast in favor, signaling a strong rejection of the compensation plan by shareholders.

  • Auditor Ratified

    Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.


Analysis · VTVT · Life Sciences

The annual meeting results reveal substantial shareholder dissatisfaction with both the election of several board members and the company's executive compensation plan. While all director nominees were technically elected, a majority of votes for five out of seven nominees were 'withheld,' indicating a lack of confidence. Furthermore, the non-binding advisory vote on executive compensation received very low support, with only 25.8% of votes cast in favor, signaling a clear rejection of the compensation package by a large portion of the voting shares. This indicates potential governance challenges and a need for the board to address significant shareholder concerns.

At the time of this filing, VTVT was trading at $36.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $142.9M. The 52-week trading range was $14.00 to $44.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VTVT - Latest Insights

VTVT
Jun 29, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.27
Real-time Price: $36.27 info
Change: $0 (0%) info
Market Cap: $142.864M info
VTVT
May 13, 2026, 5:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.67
Real-time Price: $36.27 info
Change: +$4.61 (+15%) info
Market Cap: $142.864M info
VTVT
May 13, 2026, 4:21 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $31.67
Real-time Price: $36.27 info
Change: +$4.61 (+15%) info
Market Cap: $142.864M info
VTVT
May 13, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $31.67
Real-time Price: $36.27 info
Change: +$4.61 (+15%) info
Market Cap: $142.864M info
VTVT
Mar 10, 2026, 4:37 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $35.02
Real-time Price: $36.27 info
Change: +$1.25 (+4%) info
Market Cap: $142.864M info
VTVT
Mar 10, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $35.02
Real-time Price: $36.27 info
Change: +$1.25 (+4%) info
Market Cap: $142.864M info
VTVT
Mar 10, 2026, 4:32 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $35.02
Real-time Price: $36.27 info
Change: +$1.25 (+4%) info
Market Cap: $142.864M info
VTVT
Feb 02, 2026, 4:18 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $38.31
Real-time Price: $36.27 info
Change: -$2.04 (-5%) info
Market Cap: $142.864M info